Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)-Hyaluronan Complex in Endometrial Cancer

Table 6

Hazard ratios for disease-free survival with 95% CIs adjusted for HAS, HA, SHAP-HA complex, UTI, MMP-2, MMP-9, TIMP-1, and the clinicopathological manifestations in patients with endometrial cancer.

Variables	Hazard ratio	95% CI	𝑃 value
Age	1.036	0.866–1.238	0.7020
Myometrial invasion (more than half)	79.594	0.194–3261.041	0.1155
Histological grade (G3)	3.407	0.146–79.578	0.4458
Lymph-vascular space involvement	0.892	0.010–77.881	0.9602
HAS1 expression	0.213	0.002–23.731	0.5203
HAS2 expression	0.273	0.010–7.258	0.4380
HAS3 expression	0.132	0.002–7.961	0.3325
HA	0.990	0.973–1.007	0.2440
SHAP-HA complex	1.773	1.010–3.111	0.0461
UTI	1.084	0.981–1.198	0.1146
MMP-2	0.993	0.976–1.011	0.4693
MMP-9	1.000	0.998–1.002	0.9204
TIMP-1	1.008	0.984–1.034	0.5074